HK1048442B - 含佐米曲坦的藥物配製劑 - Google Patents

含佐米曲坦的藥物配製劑 Download PDF

Info

Publication number
HK1048442B
HK1048442B HK03100515.3A HK03100515A HK1048442B HK 1048442 B HK1048442 B HK 1048442B HK 03100515 A HK03100515 A HK 03100515A HK 1048442 B HK1048442 B HK 1048442B
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulations
formulations containing
zolmitriptan
containing zolmitriptan
formulation
Prior art date
Application number
HK03100515.3A
Other languages
English (en)
Chinese (zh)
Other versions
HK1048442A1 (en
Inventor
Roy Dearn Alan
Louise Williamson Sarah
John Summers Simon
John Coomer Trevor
Original Assignee
阿斯特拉曾尼卡有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1048442(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 阿斯特拉曾尼卡有限公司 filed Critical 阿斯特拉曾尼卡有限公司
Publication of HK1048442A1 publication Critical patent/HK1048442A1/xx
Publication of HK1048442B publication Critical patent/HK1048442B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK03100515.3A 1999-12-03 2000-11-28 含佐米曲坦的藥物配製劑 HK1048442B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9928578 1999-12-03
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (2)

Publication Number Publication Date
HK1048442A1 HK1048442A1 (en) 2003-04-04
HK1048442B true HK1048442B (zh) 2005-05-13

Family

ID=10865629

Family Applications (2)

Application Number Title Priority Date Filing Date
HK03100515.3A HK1048442B (zh) 1999-12-03 2000-11-28 含佐米曲坦的藥物配製劑
HK03100621.4A HK1048445B (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK03100621.4A HK1048445B (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Country Status (28)

Country Link
US (2) US6750237B1 (enExample)
EP (1) EP1237551B1 (enExample)
JP (1) JP2003515559A (enExample)
KR (1) KR100670092B1 (enExample)
CN (1) CN1222287C (enExample)
AT (1) ATE291914T1 (enExample)
AU (1) AU778092B2 (enExample)
BR (1) BRPI0016138B8 (enExample)
CA (1) CA2392050C (enExample)
CZ (1) CZ301528B6 (enExample)
DE (1) DE60019162T2 (enExample)
EE (1) EE05305B1 (enExample)
ES (1) ES2236001T3 (enExample)
GB (2) GB9928578D0 (enExample)
HK (2) HK1048442B (enExample)
HU (1) HU229458B1 (enExample)
IL (2) IL149578A0 (enExample)
IS (1) IS2135B (enExample)
MX (1) MXPA02005319A (enExample)
NO (1) NO322119B1 (enExample)
NZ (1) NZ518862A (enExample)
PL (1) PL200679B1 (enExample)
PT (1) PT1237551E (enExample)
RU (1) RU2255736C2 (enExample)
SK (1) SK287228B6 (enExample)
UA (1) UA75059C2 (enExample)
WO (1) WO2001039772A1 (enExample)
ZA (1) ZA200203704B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
EP1744784A2 (en) * 2004-05-11 2007-01-24 Becton, Dickinson and Company Formulations of anti-pain agents and methods of using the same
WO2005115345A1 (en) * 2004-05-28 2005-12-08 Imaginot Pty Ltd Oral therapeutic compound delivery system
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20060211751A1 (en) * 2004-11-19 2006-09-21 Reuven Izsak Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DE602007013440D1 (de) * 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
AU2011316225B2 (en) 2010-10-15 2016-05-19 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
BR112014025907B1 (pt) 2012-04-18 2023-02-14 Contera Pharma Aps Formulação farmacêutica disponível para administração por via oral adequada para manejo aprimorado de transtornos do movimento
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
CN111432801A (zh) * 2017-12-21 2020-07-17 台湾微脂体股份有限公司 缓释型曲普坦组合物及通过皮下或类似途径使用其的方法
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT97888B (pt) * 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
GB9012672D0 (en) * 1990-06-07 1990-08-01 Wellcome Found Therapeutic heterocyclic compounds
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
EP1014943B1 (de) * 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
ES2236001T3 (es) 2005-07-16
IS2135B (is) 2006-08-15
EE200200283A (et) 2003-06-16
UA75059C2 (uk) 2006-03-15
PL357597A1 (en) 2004-07-26
GB2373726A (en) 2002-10-02
IL149578A (en) 2008-04-13
ZA200203704B (en) 2003-10-29
KR20020058051A (ko) 2002-07-12
CA2392050C (en) 2009-11-24
NO20022525D0 (no) 2002-05-28
PT1237551E (pt) 2005-07-29
NZ518862A (en) 2004-02-27
BRPI0016138B8 (pt) 2021-05-25
ATE291914T1 (de) 2005-04-15
SK287228B6 (sk) 2010-03-08
HU229458B1 (en) 2013-12-30
NO20022525L (no) 2002-05-28
NO322119B1 (no) 2006-08-14
US7220767B2 (en) 2007-05-22
GB9928578D0 (en) 2000-02-02
AU778092B2 (en) 2004-11-18
PL200679B1 (pl) 2009-01-30
SK7532002A3 (en) 2002-12-03
WO2001039772A1 (en) 2001-06-07
BR0016138B1 (pt) 2013-09-10
EP1237551B1 (en) 2005-03-30
US20040214899A1 (en) 2004-10-28
HUP0203597A3 (en) 2005-07-28
GB0214845D0 (en) 2002-08-07
CA2392050A1 (en) 2001-06-07
JP2003515559A (ja) 2003-05-07
HK1048442A1 (en) 2003-04-04
CZ301528B6 (cs) 2010-04-07
DE60019162T2 (de) 2006-02-02
DE60019162D1 (de) 2005-05-04
KR100670092B1 (ko) 2007-01-17
HK1048445A1 (en) 2003-04-04
CZ20021901A3 (cs) 2002-11-13
RU2255736C2 (ru) 2005-07-10
AU1715701A (en) 2001-06-12
CN1222287C (zh) 2005-10-12
IS6394A (is) 2002-05-24
CN1402636A (zh) 2003-03-12
HK1053430A1 (en) 2003-10-24
EP1237551A1 (en) 2002-09-11
US6750237B1 (en) 2004-06-15
MXPA02005319A (es) 2002-12-06
IL149578A0 (en) 2002-11-10
HUP0203597A2 (hu) 2003-02-28
HK1048445B (en) 2005-08-26
EE05305B1 (et) 2010-06-15
BR0016138A (pt) 2002-08-06
RU2002117649A (ru) 2004-01-27
GB2373726B (en) 2004-10-20

Similar Documents

Publication Publication Date Title
HK1048442A1 (en) Pharmaceutical formulations containing zolmitriptan
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
EP0960621A3 (en) Pharmaceutical formulations comprising sildenafil
NO308854B1 (no) Terapeutiske forbindelser, farmasøytisk akseptable salter og formuleringer inneholdende forbindelsene, samt anvendelser derav
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU5181200A (en) Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
WO1999044608A8 (en) New use
AU2001289606A1 (en) Dry powder formulation comprising racecadotril
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
AU1164601A (en) Therapeutic use and formulation
AU2001268710A1 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
AU2002332488A1 (en) R-bambuterol, its preparation and therapeutic uses
WO1998010762A3 (en) Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride
WO2001045650A3 (de) Kosmetische verwendung von rückständen aus der weinherstellung
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
AU2001254961A1 (en) Agrochemical spray treatment and spray formulations
ES2131482A1 (es) Formulacion acuosa de bambuterol.
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
AU2002322424A1 (en) Novel methods and formulations for administration of active agents
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
WO2001060344A3 (en) Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections
HK1051647A (en) Oral, nasal and pulmonary dosage formulations of copolymer 1

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20201127